Publications by authors named "Rodney Sinclair"
Background: The light-emitting diode cap being investigated is FDA cleared for the treatment of androgenetic alopecia (AGA).
Objective: Evaluating 3 versions of a red and blue light LED cap: (1) 625- and 660-nm red light, (2) 425-nm blue light, and (3) both 425-nm blue light and 625- and 660-nm red light against sham.
Patients And Methods: Twenty-six-week, multicenter, randomized, controlled, double-blinded study.
Australian dermatologists' prescribing behaviours for female androgenetic alopecia.
Australas J Dermatol
December 2024
Female androgenetic alopecia (FAGA) affects approximately half of women during their lifetime and can have significant psychological impact. Despite its prevalence, treatment options have traditionally been limited. In this study, we examined the current prescribing patterns of Australian dermatologists for FAGA (n = 54), including the use of spironolactone, systemic minoxidil, topical minoxidil and combination treatments.
View Article and Find Full Text PDFPainful bilateral gynaecomastia secondary to topical finasteride.
Australas J Dermatol
December 2024
Article Synopsis
- Small studies suggest that low-dose oral minoxidil (LDOM) might be effective and safe for hair loss, but more extensive research and guidelines are needed.* -
- An expert consensus statement was developed involving 43 dermatologists to standardize LDOM prescribing practices, covering various aspects like indications, dosing, and monitoring.* -
- The consensus reached includes 76 relevant points, but topics related to pediatric use and titration protocols need further investigation, highlighting gaps in research for younger patients.*
Article Synopsis
- The ALLEGRO study assessed the effectiveness and safety of ritlecitinib, a treatment for alopecia areata (AA), focusing on patient-reported hair loss outcomes.
- Patients aged 12 and older with significant scalp hair loss participated in a 48-week trial comparing different dosages of ritlecitinib to a placebo.
- Results showed that 5-36% of ritlecitinib patients reported improved hair loss after 24 weeks, which correlated with positive changes in emotional symptoms and activity limitations, indicating the treatment's beneficial effects.
Article Synopsis
- This study investigates the effectiveness and safety of ritlecitinib, a treatment for alopecia areata (AA), over 48 weeks in patients with varying responses by Week 24.
- Results showed that over 85% of patients who had good responses at Week 24 maintained their improvement, while some nonresponders also began to show better results by Week 48.
- The study had a small sample size, but it concludes that ritlecitinib can lead to sustained hair regrowth in many patients with AA.
Article Synopsis
- A post-hoc analysis of the ALLEGRO study assessed the effects of ritlecitinib, an oral JAK inhibitor, in treating patients aged 12 and older with alopecia totalis (AT) and alopecia universalis (AU) over 48 weeks.
- Out of 718 patients, those treated with ritlecitinib showed significantly higher hair regrowth response rates compared to the placebo group, improving from week 24 to week 48.
- Ritlecitinib was well tolerated, demonstrating clinical efficacy and an acceptable safety profile for patients with both AT and AU.
Low-dose oral minoxidil for the treatment of monilethrix: A retrospective review.
J Eur Acad Dermatol Venereol
September 2024
Clinician-reported outcome measures (ClinROMs) are an important part of disease assessment in daily practice and clinical trials. There is a broad disagreement on the most appropriate ClinROM for a comprehensive assessment of alopecia areata (AA) severity. This paper aims to identify the currently available ClinROMs for AA through a systematic literature search, address their practical strengths and weaknesses, and identify the road ahead for future research.
View Article and Find Full Text PDFArticle Synopsis
- Frontal fibrosing alopecia (FFA) is a type of hair loss marked by receding hairlines, itching, and small facial bumps, with many treatments available but some symptoms proving hard to treat.
- A review of 12 studies found that oral isotretinoin may significantly improve treatment-resistant facial papules in FFA patients, although the current evidence comes mainly from retrospective studies and case reports.
- The findings suggest that isotretinoin could be a beneficial treatment option, but more rigorous research is needed to confirm its effectiveness.
Article Synopsis
- - The study aimed to assess patient satisfaction with hair growth in people with alopecia areata (AA) receiving ritlecitinib or a placebo, focusing on how well patients felt their treatment was working compared to what clinicians observed.
- - In the ALLEGRO-2b/3 trial, 718 AA patients with significant scalp hair loss were given either ritlecitinib or a placebo for 24 weeks, after which some switched treatments; satisfaction was measured through a specific survey evaluating different aspects of hair growth.
- - Results showed that at week 24, satisfaction with hair growth was significantly higher in ritlecitinib groups (up to 67.5%) compared to placebo (22.6%),
Background: Alopecia areata (AA) is an autoimmune hair loss disorder characterised by collapse of hair follicle immune privilege and mediated by autoreactive CD8+ T lymphocytes and natural killer cells. Treatment is often unsatisfactory. The Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is implicated in the pathogenesis of AA and Janus Kinase inhibitor (JAKi) medications are promising emerging treatments for AA.
View Article and Find Full Text PDFArticle Synopsis
- * Data from 112 patients revealed high scores for pruritus, disease severity, and quality of life issues, with many patients reporting inadequate control of their condition.
- * The findings indicate that AD significantly affects various aspects of life for ANZ patients, suggesting a need for improved treatment options.
Introduction: To understand the experiences of adolescent and adult patients living with alopecia areata (AA) in Australia regarding symptom severity and the impact on psychosocial well-being and work/classroom productivity.
Materials And Methods: A cross-sectional online patient survey among adolescent and adult patients diagnosed with AA was recruited via the Australia Alopecia Areata Foundation. Patient-reported outcomes were also assessed.